ClinicalTrials.gg

Program

delpacibart zotadirsen

In Novartis’s pipeline, PMO mediated exon 44 skipping. Its studies are mostly in Muscular Dystrophy, Duchenne · Myotonic Dystrophy, led by Novartis.

Furthest: phase 3, since May 8, 20263 company-led studies, 2 open or runningNext primary completion: Apr 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis32 open or runningphase 3since May 8, 2026Dec 6, 2022Apr 30, 2027phase 2 · NCT06244082
  • Named in Novartis’s own pipeline as KPE179 (del-zota), phase 4, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 6, 2022First study: phase 2 study in Muscular Dystrophy, DuchenneFirst studyNCT05670730 · 70 enrolled · United States
  2. Jan 26, 2024Phase 2 study in Muscular Dystrophy, DuchenneNCT06244082 · 39 enrolled · United States
  3. May 8, 2026Phase 3 study in Muscular DystrophiesPhase 3 reachedNCT07587242 · 70 planned · Australia, Belgium, Canada and more

Ahead

  1. Apr 30, 2027Primary completion: phase 2 study in Muscular Dystrophy, DuchenneNCT06244082
  2. May 2029Primary completion: phase 3 study in Muscular DystrophiesNCT07587242

TargetBeta

“PMO mediated exon 44 skipping”the company's pipeline, read by Claude · source

Other programs on DMD

ProgramCompanyFurthest phaseStudies
delandistrogene moxeparvovecruleSarepta Therapeuticsphase 41

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07587242Muscular Dystrophies · Australia, Belgium, Canada and more3RecruitingMay 202970
NCT06244082Muscular Dystrophy, Duchenne · United States2Active, not recruitingApr 30, 202739
NCT05670730Muscular Dystrophy, Duchenne · United States2CompletedNov 25, 202470

How it is read

Names in the registry

  • “AOC 1044”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.